FMP
NASDAQ
86.82 USD
-3.68 (-4.24%)
Ms. Kathryn Haviland
Healthcare
Biotechnology
https://www.blueprintmedicines.com
NASDAQ
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU...
0001597264
US09627Y1091
09627Y109
45 Sidney Street
617 374 7580
US
655
Apr 30, 2015
0001597264
NASDAQ
Biotechnology
Healthcare
09627Y109
US09627Y1091
US
86.82
0.63
809.21k
5.32B
-
41.54-101.0
46.94
-
-
-
-
-10.37
-
https://www.blueprintmedicines.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.